MedTrace Logo

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

NCT03089203 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-02-23

No results posted yet for this study

Summary

This is a single center, single arm Phase I study to establish the safety and feasibility of intravenously administered lentivirally transduced dual PSMA-specific/TGFβ-resistant CAR modified autologous T cells (CART-PSMA-TGFβRDN cells) in patients with metastatic castrate resistant prostate cancer.

Conditions

Interventions

BIOLOGICAL

CART-PSMA-TGFβRDN cells

autologous CAR T cells

DRUG

Cyclophosphamide

300 mg/m2/day given over 3 days

DRUG

Fludarabine

30 mg/m2/day given over 3 days

Sponsors & Collaborators

Principal Investigators

  • Naomi Haas, MD · Universtiy of Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-08
Primary Completion
2038-09-08
Completion
2038-12-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03089203 on ClinicalTrials.gov